Biogen cans plan to test aducanumab in Alzheimer's prevention

Biogen has decided against starting a phase 3 trial of aducanumab in the prevention of Alzheimer’s disease. The study was the one option for further development of aducanumab that Biogen left open when it revealed the failure of its main pivotal program last month.